Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Stroke Research

Study Title:  A Double-Blind, Controlled Phase 2B Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients with Chronic Motor Deficit from Ischemic Stroke.   (Identifier: NCT02448641)

Study Purpose:  Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke.

Principal Investigator: Mouhammad Jumaa, M.D.

Study Coordinator:  For more information email Andrea Korsnack, RN, CNRN, CCRC or call 419.383.3801.


Study Title:  Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial (Identifier: NCT00991029)

Study Purpose:  A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor ischemic strokes (with an NIH Stroke Scale [NIHSS] score less than or equal to 3). TIAs are common [25], and are often harbingers of disabling strokes. Composite endpoint of new ischemic vascular events: ischemic stroke, myocardial infarction or ischemic vascular death at 90 days.

Principal Investigator: Mouhammad Jumaa, M.D.

Study Coordinator:  For more information email Andrea Korsnack, RN, CNRN, CCRC or call 419.383.3801.


 

 

Last Updated: 9/11/17